Monitoring neonatal hypoglycemia with the Accu-chek advantage II glucose meter: the cautionary tale of galactosemia.
نویسندگان
چکیده
To the Editor: Hand-held glucose meters are a practical solution for measuring glucose in neonatal intensive care units and special care nurseries because of their portability, the immediacy of results, and minimal blood volume requirements compared with dispatching samples for central laboratory analysis. We have used the Roche Accu-chek Advantage II meter for some time in our neonatal intensive care unit, but we no longer use it in view of the following findings. Nonidentical twins, born 4 weeks prematurely, were managed in our special care nursery. Twin 2 was found to have increasing glucose over the first 24 h, reaching a maximum of 16.8 mmol/L as measured at the point of care (POC) with the Accu-chek Advantage II meter. When a sample was sent to the laboratory for confirmation of this increased glucose, the laboratory result (measured with the hexokinase assay on a Dade-Behring Dimension RxL analyzer) was only 1.0 mmol/L. Additional investigations (including galactitol measurements) later confirmed that the baby suffered from galactosemia. Subsequently, we compared the effects of galactose addition to wholeblood samples on results of the Accuchek Advantage II, three other commonly used devices for POC measurement of blood glucose, and a hexokinase method on a Dade-Behring Dimension RxL analyzer (Fig. 1). Galactose (2.5–20 mmol/L) produced an equimolar overestimation of glucose by the Accu-chek Advantage II, indicating no discrimination between glucose and galactose by this device, whereas the other methods were unaffected. Glucose methods that use hexokinase and POC devices that use glucose oxidase (e.g., the AVL OMNI 9 analyzer and the Medisense Precision Q.I.D.) were not affected by galactose. Although it would appear that the discrepancy found with the Accu-chek Advantage II could be caused by the use of glucose dehydrogenase (GDH) to measure glucose by this device, we found that two other POC glucose measurement systems that also use GDH, the MediSense Optium glucose analyzer (Fig. 1) and the HemoCue B-Glucose analyzer (Joakim Hagvik, HemoCue, personal communication) were not affected by galactose. Thus it appears that it may be the source of the GDH or its formulation that leads to the measurement of galactose as glucose. The product information sheet with Accu-chek Advantage II glucose reagent strips indicates that “Galactose 10 mg/dL (0.56 mmol/L) may give falsely increased results”. We suggest that specific reference should be made to the equimolar interference of galactose with glucose and the possibility of gross overestimation of glucose in the case of galactosemia. We also recommend that all unexpectedly high POC results must be confirmed by laboratory measurement before initiation of treatment.
منابع مشابه
Improving Self-Monitoring of Blood Glucose among Adults with Type 1 Diabetes: Results of the Mobile™ Study
INTRODUCTION The objective of this study was to determine whether people with type 1 diabetes are more likely to self-monitor their blood glucose (SMBG) as recommended by their diabetes health care professional using the Accu-Chek Mobile™ (F. Hoffmann-La Roche AG, Basel, Switzerland) monitoring system compared to the Freestyle Optium™ (Abbott, North Chicago, IL, USA). METHODS Thirty-five part...
متن کاملPoint-of-care glucose analysis in neonates using modified quinoprotein glucose dehydrogenase.
BACKGROUND Asymptomatic hypoglycemia in neonates may contribute to neurologic deficits during development. Whole-blood glucose sensors are often imprecise and inaccurate at the low glucose concentrations found in neonates. SUBJECTS AND METHODS In this study, a glucose sensor using a mutated glucose dehydrogenase that does not cross-react significantly with maltose was evaluated at three pedia...
متن کاملRole of Mobile Technology to Improve Diabetes Care in Adults with Type 1 Diabetes: The Remote-T1D Study iBGStar® in Type 1 Diabetes Management
INTRODUCTION The role of mobile technology in patient-reported outcomes (PRO) and glycemic control in adults with type 1 diabetes (T1D) needs further evaluation. METHODS The single-center, prospective, 6-month, open-label, investigator-initiated study randomized 100 subjects with T1D in a 1:1 fashion to a control group using self-monitoring of blood glucose (SMBG) with Accu-Chek Nano® and an ...
متن کاملمقایسه قدرت دستگاه گلوکومتر Accu-chek با Elite در تشخیص دیابت با استفاده از خونریزی متعاقب Probing
Abstract Background: Recent studies have assessed the validity of glucometer devices in estimating the glucose level of gingival blood during routine periodontal examination (Bleeding On Probing). The purpose of this study was to evaluate whether blood oozing from gingival tissues during routine periodontal examination can be used for determining g...
متن کاملContinuous glucose monitoring in newborn infants: how do errors in calibration measurements affect detected hypoglycemia?
Neonatal hypoglycemia is common and can cause serious brain injury. Continuous glucose monitoring (CGM) could improve hypoglycemia detection, while reducing blood glucose (BG) measurements. Calibration algorithms use BG measurements to convert sensor signals into CGM data. Thus, inaccuracies in calibration BG measurements directly affect CGM values and any metrics calculated from them. The aim ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical chemistry
دوره 48 11 شماره
صفحات -
تاریخ انتشار 2002